» Articles » PMID: 34905501

IGFBP-6/sonic Hedgehog/TLR4 Signalling Axis Drives Bone Marrow Fibrotic Transformation in Primary Myelofibrosis

Abstract

Primary myelofibrosis is a Ph-negative chronic myeloproliferative neoplasm characterized by bone marrow fibrosis and associated with the involvement of several pathways, in addition to bone marrow microenvironment alterations, mostly driven by the activation of the cytokine receptor/JAK2 pathway. Identification of driver mutations has led to the development of targeted therapy for myelofibrosis, contributing to reducing inflammation, although this currently does not translate into bone marrow fibrosis remission. Therefore, understanding the clear molecular cut underlying this pathology is now necessary to improve the clinical outcome of patients. The present study aims to investigate the involvement of IGFBP-6/sonic hedgehog /Toll-like receptor 4 axis in the microenvironment alterations of primary myelofibrosis. We observed a significant increase in IGFBP-6 expression levels in primary myelofibrosis patients, coupled with a reduction to near-normal levels in primary myelofibrosis patients with JAK2V617F mutation. We also found that both IGFBP-6 and purmorphamine, a SHH activator, were able to induce mesenchymal stromal cells differentiation with an up-regulation of cancer-associated fibroblasts markers. Furthermore, TLR4 signaling was also activated after IGFBP-6 and purmorphamine exposure and reverted by cyclopamine exposure, an inhibitor of the SHH pathway, confirming that SHH is involved in TLR4 activation and microenvironment alterations. In conclusion, our results suggest that the IGFBP-6/SHH/TLR4 axis is implicated in alterations of the primary myelofibrosis microenvironment and that IGFBP-6 may play a central role in activating SHH pathway during the fibrotic process.

Citing Articles

Hedgehog Signaling Pathway in Fibrosis and Targeted Therapies.

Hu Y, Peng L, Zhuo X, Yang C, Zhang Y Biomolecules. 2025; 14(12.

PMID: 39766192 PMC: 11727624. DOI: 10.3390/biom14121485.


Mechanobiology and Primary Cilium in the Pathophysiology of Bone Marrow Myeloproliferative Diseases.

Tiberio F, Coda A, Tosi D, Luzi D, Polito L, Liso A Int J Mol Sci. 2024; 25(16).

PMID: 39201546 PMC: 11354938. DOI: 10.3390/ijms25168860.


(+)-Lipoic acid reduces mitochondrial unfolded protein response and attenuates oxidative stress and aging in an in vitro model of non-alcoholic fatty liver disease.

Longhitano L, Distefano A, Musso N, Bonacci P, Orlando L, Giallongo S J Transl Med. 2024; 22(1):82.

PMID: 38245790 PMC: 10799515. DOI: 10.1186/s12967-024-04880-x.


ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis.

Duminuco A, Chifotides H, Giallongo S, Giallongo C, Tibullo D, Palumbo G Cancers (Basel). 2024; 16(1).

PMID: 38201581 PMC: 10778144. DOI: 10.3390/cancers16010154.


Engagement of Mesenchymal Stromal Cells in the Remodeling of the Bone Marrow Microenvironment in Hematological Cancers.

Giallongo S, Duminuco A, Dulcamare I, Zuppelli T, La Spina E, Scandura G Biomolecules. 2023; 13(12).

PMID: 38136573 PMC: 10741414. DOI: 10.3390/biom13121701.


References
1.
Jensen M, Holten-Andersen M, Riisbro R, de Nully Brown P, Larsen M, Kjeldsen L . Elevated plasma levels of TIMP-1 correlate with plasma suPAR/uPA in patients with chronic myeloproliferative disorders. Eur J Haematol. 2003; 71(5):377-84. DOI: 10.1034/j.1600-0609.2003.00096.x. View

2.
Rameshwar P, Oh H, Yook C, Gascon P, Chang V . Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis. Acta Haematol. 2002; 109(1):1-10. DOI: 10.1159/000067268. View

3.
Verstovsek S, Manshouri T, Pilling D, Bueso-Ramos C, Newberry K, Prijic S . Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis. J Exp Med. 2016; 213(9):1723-40. PMC: 4995084. DOI: 10.1084/jem.20160283. View

4.
Chagraoui H, Komura E, Tulliez M, Giraudier S, Vainchenker W, Wendling F . Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. Blood. 2002; 100(10):3495-503. DOI: 10.1182/blood-2002-04-1133. View

5.
Sanfilippo C, Castrogiovanni P, Imbesi R, Kazakowa M, Musumeci G, Blennow K . Sex difference in CHI3L1 expression levels in human brain aging and in Alzheimer's disease. Brain Res. 2019; 1720:146305. DOI: 10.1016/j.brainres.2019.146305. View